WAT icon

Waters Corp

306.38 USD
+2.70
0.89%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
306.38
0.00
0%
1 day
0.89%
5 days
2.31%
1 month
5.87%
3 months
-9.72%
6 months
-19.83%
Year to date
-16.8%
1 year
-8.1%
5 years
56.74%
10 years
150.8%
 

About: Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Employees: 7,600

0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

229% more call options, than puts

Call options by funds: $19.1M | Put options by funds: $5.8M

27% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 64

2.37% more ownership

Funds ownership: 95.77% [Q1] → 98.13% (+2.37%) [Q2]

1% more funds holding

Funds holding: 755 [Q1] → 759 (+4) [Q2]

1% less repeat investments, than reductions

Existing positions increased: 272 | Existing positions reduced: 275

3% less capital invested

Capital invested by funds: $20.9B [Q1] → $20.4B (-$571M) [Q2]

11% less funds holding in top 10

Funds holding in top 10: 9 [Q1] → 8 (-1) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$315
3% upside
Avg. target
$348
14% upside
High target
$385
26% upside

5 analyst ratings

positive
40%
neutral
60%
negative
0%
Deutsche Bank
Justin Bowers
$315
Hold
Maintained
5 Aug 2025
Wells Fargo
Brandon Couillard
$315
Equal-Weight
Maintained
5 Aug 2025
Jefferies
Tycho Peterson
$385
Buy
Maintained
4 Aug 2025
Baird
Catherine Ramsey
$352
Outperform
Maintained
16 Jul 2025
B of A Securities
Derik De Bruin
$375
Neutral
Maintained
26 Jun 2025

Financial journalist opinion

Based on 3 articles about WAT published over the past 30 days

Neutral
Seeking Alpha
14 days ago
Waters Corporation (WAT) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Waters Corporation (NYSE:WAT ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 9:30 AM EDT Company Participants Udit Batra - President, CEO & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst Let's start. Thanks, everybody, for sticking with us.
Waters Corporation (WAT) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Positive
Zacks Investment Research
15 days ago
Waters (WAT) Up 5.4% Since Last Earnings Report: Can It Continue?
Waters (WAT) reported earnings 30 days ago. What's next for the stock?
Waters (WAT) Up 5.4% Since Last Earnings Report: Can It Continue?
Neutral
PRNewsWire
23 days ago
Waters Corporation to Present at the Wells Fargo Healthcare Conference
MILFORD, Mass. , Aug. 26, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Waters Corporation to Present at the Wells Fargo Healthcare Conference
Neutral
Seeking Alpha
1 month ago
Waters Corporation (WAT) Q2 2025 Earnings Call Transcript
Waters Corporation (NYSE:WAT ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Amol Chaubal - Senior VP & CFO Caspar Tudor - Head of Investor Relations Udit Batra - President, CEO & Director Conference Call Participants Catherine Walden Ramsey Schulte - Robert W. Baird & Co. Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Jack Meehan - Nephron Research LLC Puneet Souda - Leerink Partners LLC, Research Division Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division Sung Ji Nam - Scotiabank Global Banking and Markets, Research Division Tycho W.
Waters Corporation (WAT) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates
Waters (WAT) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $2.63 per share a year ago.
Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates
Positive
The Motley Fool
1 month ago
Waters (WAT) Q2 Revenue Jumps 9%
Waters (WAT) Q2 Revenue Jumps 9%
Waters (WAT) Q2 Revenue Jumps 9%
Neutral
PRNewsWire
1 month ago
Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results
Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currency GAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customers Recurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growth In constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expected Raising full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and raising full-year 2025 non-GAAP EPS guidance to $12.95 to $13.05 Second Quarter 2025 MILFORD, Mass. , Aug. 4, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the second quarter of 2025.
Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results
Positive
Zacks Investment Research
1 month ago
Why Waters (WAT) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Waters (WAT) is a Top Growth Stock for the Long-Term
Positive
Zacks Investment Research
1 month ago
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
Positive
Zacks Investment Research
1 month ago
Waters (WAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Charts implemented using Lightweight Charts™